Steven Nissen
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cardiology Network |
 Discuss Steven Nissen further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Steven Nissen (b.1949), a heart specialist, is chairman of cardiovascular medicine at the Cleveland Clinic.
He first gained prominence when he developed techniques in 1987 to thread miniaturized ultrasound imaging devices into a patient's heart to reveal the exact composition of plaques causing the early stages of artery damage. This allowed much easier evaluation of anticholesterol medications.
His efforts in 2004 linked COX-2 inhibitors such as Celebrex and Merck's Vioxx with heart attacks, and prevented Merck's similar product, Arcoxia, from being approved. In 2005, he attacked the experimental diabetes drug Pargluva, from Bristol-Myers Squibb, for its serious heart risks. A Food and Drug Administration advisory panel had strongly recommended approval, but Pargluva was withdrawn.
In 2007, he found that the Avandia diabetes drug produced by GlaxoSmithKline carried high cardiovascular risks, leading to a warning by the Food and Drug Administration and a sales loss of about 30 percent for the drug. [1]
In 2007, he was named one of the 100 Most Influential People in the world (Time 100) by Time Magazine. [1]
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
